- $0.45m
- $0.45m
- $2.55m
Brief: NanoVibronix Says Co Has Determined To Cancel Special Meeting
Brief: Nanovibronix Announces Agreement For Clinical Study Of Uroshield At The University Of Michigan
Brief: Nanovibronix Regains Nasdaq Compliance
Brief: Nanovibronix Issues Letter To Shareholders
Brief: Nanovibronix Gains Approval For Inclusion Of Uroshield Products In Nhs Prescription Services’ Drug Tariff
Brief: Nanovibronix Cites Positive Results From Independent Testing Of Uroshield
Brief: Nanovibronix Says Painshield Is Not Reimbursable Under Medicare And Medicaid At This Time
Brief: Nanovibronix Inc Applies For Inclusion Of Uroshield Products In Nhs Prescription Services' Drug Tariff
Brief: Nanovibronix Extends Distribution Agreement With Its Largest Distributor For Painshield And Painshield Plus
Brief: Nanovibronix Inc Files For Mixed Shelf Of Up To $50 Million – SEC Filing
Brief: Nanovibronix Says Nasdaq Granted Co's Request For Continued Listing Pursuant To Extension Through Nov 20
Brief: NanoVibronix Files For Offering Of Shares Of Common Stock, Together With Warrants Size Not Discosed-SEC Filing
Brief: NanoVibronix Announces Distribution Agreement With Mio-Guard
Brief: Nanovibronix Receives Notice Of Delisting Or Failure From Nasdaq
Brief: Nanovibronix Issues Letter To Shareholders
Brief: Nanovibronix Receives Positive Final Results Of Independent Lifecycle Testing Of Painshield Prompted By Centers For Medicare And Medicaid Services (CMS)
Brief: Nanovibronix Files Provisional U.S. Patent Application For Uroshield Ultra
Brief: NanoVibronix Announces Positive Results From Independent Product Trial of UroShield For Patients With Spinal Cord Injury
Brief: Nanovibronix Regains Nasdaq Compliance